Drug intelligence / Profile preview

GSK3439171A

Development stage: Phase 1
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

GSK3439171A is a potent, reversible, and highly selective small molecule inhibitor of hematopoietic prostaglandin D synthase (H-PGDS), an enzyme involved in the biosynthesis of prostaglandin D2 (PGD2). PGD2 is implicated in inflammatory processes and certain disease states. The drug was developed by GSK for potential use in conditions such as Duchenne muscular dystrophy. Early clinical studies have focused on evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult participants[3][9][5].

Targets

HPGDS (Haematopoietic prostaglandin D synthase)

Beyond the preview

Go deeper on GSK3439171A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK3439171A.

Explore the full profile